Favorable Effect of Bromocriptine and Pentoxifylline in Mild Graves Disease Orbitopathy: A Randomized, Open, Clinical Trial

Graves’ orbitopathy (GO) is the most frequent extra thyroidal manifestation of Graves’ disease. Treatment for mild cases consists in euthyroidism restoration and topical treatments. Aim: To evaluate the effect of bromocriptine (BRC) or pentoxifylline (PTX) added to methimazole (MTZ) in proptosis, clinical activity, and quality of life in individuals with mild GO. Methods: Randomized, open, clinical trial. Forty-five patients with mild GO with an onset of less than one year were randomly assigned to MTZ, MTZ+BRC, or MTZ+PTX treatment during one year. Proptosis was measured with exophthalmometry, clinical activity was evaluated using the Clinical Activity Score (CAS), and the Graves’ Orbitopathy Quality Of Life (GO-QOL) questionnaire was also applied. Results: Thirty-five patients were analyzed, 13 assigned to MTZ, 9 to MTZ+BRC, and 13 to MTZ+PTX. After one year, a decrease in proptosis was documented in the MTZ+BRC group. Proptosis on right eye (OD) decreased from 20 [18-21] to 18 [16-18] mm (p= 0.006), and on left eye (OS) from 20 [19-20] to 18 [16-18] (p= 0.006). MTZ+PTX treatment also decreased proptosis. In OD from 19 [17.5-19] to 16.5 mm [16-19] (p= 0.120) and in OS from 19 [17.5-19] to 17 [16-20] (p= 0.025). No change was observed on the MTZ group. The CAS and GO-QOL scores significantly improved in all groups. Conclusions: BRC or PTX treatments added to MTZ improved proptosis in individuals with recent onset, mild GO. CAS and quality of life similarly improved in all groups.

• Publication year

  2017

• Venue

  Unknown venue

• Publication date

  2017-06-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.15226/2374-6890/4/2/00176
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Serum concentration of VEGF and PDGF-AA in patients with active thyroid orbitopathy before and after immunosuppressive therapy.

  2014cited by this paper
• Markers of Inflammation and Fibrosis in the Orbital Fat/Connective Tissue of Patients with Graves' Orbitopathy: Clinical Implications

  2014cited by this paper
• Cabergoline reduces cell viability in non functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretion

  2013cited by this paper
• Graves' Orbitopathy: Imperfect Treatments for a Rare Disease

  2013influential reference
• Prolactin and Autoimmunity

  2012influential reference
• Selenium and the Course of Mild Graves' Orbitopathy

  2012cited by this paper
• Epidemiology of Graves' orbitopathy (GO) and relationship with thyroid disease.

  2012cited by this paper
• Prolactin--not only lactotrophin. A "new" view of the "old" hormone.

  2012influential reference
• Treatment of mild to moderate Graves' ophthalmopathy with sodium diclofenac: a pilot study.

  2011cited by this paper
• Antithyroid drug regimen for treating Graves' hyperthyroidism.

  2010influential reference
• Immunoregulation of autocrine prolactin: suppressing the expression of costimulatory molecules and cytokines in T lymphocytes by prolactin receptor knockdown.

  2010influential reference
• Positive effect of bromocriptine treatment in Graves disease orbitopathy.

  2009cited by this paper
• Consensus Statement of the European Group on Graves' Orbitopathy (EUGOGO) on Management of Graves' Orbitopathy

  2008influential reference
• Consensus statement of the European Group on Graves' orbitopathy (EUGOGO) on management of GO.

  2008cited by this paper
• Colchicine in the treatment of the inflammatory phase of Graves' ophthalmopathy: a prospective and randomized trial with prednisone.

  2006cited by this paper
• Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.

  2005cited by this paper
• Pentoxifylline (PTX) - an Alternative Treatment in Graves' Ophthalmopathy (Inactive Phase): Assessment by a Disease Specific Quality of Life Questionnaire and by Exophthalmometry in a Prospective Randomized Trial

  2004cited by this paper
• Current perspective on the pathogenesis of Graves' disease and ophthalmopathy.

  2003cited by this paper
• Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy.

  2002cited by this paper
• Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments

  2001cited by this paper
• The roles of prolactin, growth hormone, insulin-like growth factor-I, and thyroid hormones in lymphocyte development and function: insights from genetic models of hormone and hormone receptor deficiency.

  2000cited by this paper
• Antioxidant agents in the treatment of Graves' ophthalmopathy.

  2000cited by this paper
• Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor.

  1999cited by this paper
• Exophthalmometry in Mexican adults.

  1999cited by this paper
• Prolactin and Neuroimmunomodulation: In Vitro and in Vivo Observations

  1999cited by this paper
• Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study.

  1997cited by this paper
• Clinical activity score as a guide in the management of patients with Graves' ophthalmopathy

  1997cited by this paper
• Pharmacological aspects of pentoxifylline with emphasis on its inhibitory actions on hepatic fibrogenesis.

  1997cited by this paper
• Quality of Life in Patients with Graves' Ophthalmopathy is Markedly Decreased: Measurement by the Medical Outcomes Study Instrument

  1997cited by this paper
• Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture.

  1996cited by this paper
• Natural history of thyroid associated ophthalmopathy

  1995cited by this paper
• Thyroid-associated ophthalmopathy: pathogenesis and clinical management.

  1995cited by this paper
• The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota.

  1994cited by this paper
• Immunosuppressive property of bromocriptine on human B lymphocyte function in vitro

  1993cited by this paper
• Bromocriptine therapy for thyroid ophthalmopathy.

  1989cited by this paper
• [Dynamics of clinico-immunologic indices in patients with endocrine ophthalmopathy undergoing treatment with the preparation parlodel].

  1988cited by this paper

• No citing papers are available for this paper.